SINOVAC-CoronaVac

What is Sinovac-CoronaVac?

› CoronaVac, also known as the Sinovac COVID-19 vaccine, is an

inactivated virus COVID-19 vaccine developed by the Chinese
company Sinovac Biotech.
› Sinovac Biotech - is a Chinese biopharmaceutical company
that focuses on the research, development, manufacture, and
commercialization of vaccines that protect against human
infectious diseases. The company is based in Haidian District,
Beijing in China.
– The CEO of Sinovac Biotech is Yin Weidong.
SINOVAC
› WHOLE VIRUS VACCINE
› What to know: The whole virus vaccine uses a weakened or deactivated
form of the pathogen that causes COVID-19 to trigger protective
immunity to it. 
› The two vaccines mentioned above – Sinopharm and Sinovac – both use
inactivated pathogens, therefore they cannot infect cells and replicate,
but can trigger an immune response.
› Benefits: According to Gavi, the Vaccine Alliance (GAVI), the advantages
of an inactivated whole virus vaccine include the fact its technology is
well established, it is suitable for people with compromised immune
systems, and it’s relatively simple to manufacture.
HISTORY
› Sinovac has received approval from China's National Medical Products Administration to
conduct Phase I/II human clinical trials in China on April 13, 2020, to determine the
vaccine candidate's safety, tolerance, dosage, and immunization schedule.
› On May 22, 2020, Sinovac announced a transaction in which Advantech Capital and Vivo
Capital have invested $15 million in Sinovac Research and Development Co., Ltd.
("Sinovac R&D"), a wholly-owned subsidiary of Sinovac, to further the development of an
inactivated vaccine against COVID-19 named CoronaVac.
› On June 13, 2020, Sinovac announced positive preliminary results of the phase I/II clinical
trial for the Company's CoronaVac vaccine, which showed favorable immunogenicity and
safety profiles. The phase II clinical trial results show that the vaccine induces
neutralizing antibodies 14 days after the vaccination with a 0 and 14-day schedule. The
neutralizing antibody seroconversion rate is above 90%, which concludes the vaccine
candidate can induce a positive immune response.
› On July, Sinovac launches a Phase 3 trial in Brazil, followed by others
in Indonesia and Turkey. Reuters reports that the Chinese government gave the Sinovac
vaccine emergency approval for limited use.
History
› October Authorities in the eastern Chinese city of Jiaxing
announce they are giving CoronaVac to people in relatively
high-risk jobs, including medical workers, port inspectors and
public service personnel.
› Oct. 19 Officials in Brazil say that Sinovac is the safest of five
vaccines they are testing in Phase 3 trials.
› November Sinovac publishes the details of its Phase 1/2 trial in
a medical journal, showing a comparatively modest
production of antibodies. Only a Phase 3 trial will demonstrate
if that is enough to protect people from Covid-19.
History
› Nov. 19 The Brazilian government announces that they paused the country’s
Sinovac trial the previous month because of an adverse event. The details of
the pause were murky, raising suspicions that politics were involved. Two
days after the announcement, the trial was allowed to resume. The Brazilian
trial has recorded enough cases of Covid-19 to let researchers determine
Sinovac’s efficacy. They expect to release their results by Dec. 23.
› December Sinovac says it expects to manufacture 300 million doses in 2020
and increase capacity to an annual production of 600 million doses.
› Dec. 23 Brazilian researchers announce that CoronaVac has an efficacy
of over 50 percent.
› Dec. 24 Turkish officials announce that the vaccine has an efficacy rate
of 91.25 percent.
History
› Jan. 7, 2021 Researchers in Brazil announce that CoronaVac has an
efficacy of 78 percent. None of the vaccinated volunteers in their
Phase 3 trial developed severe or moderate cases of Covid-19. But
the efficacy estimate was based on the vaccine’s performance in a
subgroup of volunteers. The overall efficacy is not formally released.
› Jan. 11 Indonesia authorizes the vaccine for emergency use.
› Jan. 13 Researchers in Brazil announce that CoronaVac has an
overall efficacy of just over 50 percent. Turkey authorizes the
vaccine for emergency use.
› Feb. 6 Sinovac announces that China has given
CoronaVac conditional approval.
History
› March 13 China asks visa applicants to get inoculated with
Chinese-made coronavirus vaccines.
› April 1 Sinovac announces that its capacity has increased to 2
billion doses after completing a third production line.
SINOVAC-CORONAVAC
WHO MAY RECEIVE THE VACCINE?
› Persons belonging to identified priority groups and aged 18 to
59  with low exposure to COVID-19 infection may receive SARS-
CoV-2 Vaccine (Vero cell), Inactivated [CoronaVac], “Commonly
known as Sinovac”.
WHO MAY “NOT” RECEIVE THE VACCINE?
› Persons with history of anaphylaxis or allergic reactions (of any
severity) that occur within 4 hours after receiving the first dose
of the vaccine
› Persons with high risk of exposure to COVID-19 infection
› Persons under 18  or over 59 years old. 
COMPOSITION OF THE VACCINE
› SARS-CoV-2 Vaccine (Vero cell), Inactivated [CoronaVac] contains an
inactivated SARS-CoV-2 virus (CZ02). The vaccine is non-infectious as it does
not contain active viral particles.
› The product is manufactured by inoculation of SARS-CoV-2 virus into African
Green Monkey Kidney Cell (Vero Cell), then the virus is incubated, harvested,
inactivated, concentrated, purified and adsorbed by aluminum hydroxide.
How does this vaccine compare to other vaccines already in use?
› We cannot compare the vaccines head-to-head due to the different
approaches taken in designing the respective studies, but overall, all of
the vaccines that have achieved WHO Emergency Use Listing are highly
effective in preventing severe disease and hospitalization due to COVID-
19.

ADVERSE REACTIONS
HYPERSENSITIVITY REACTIONS
› Pain and reaction (rash,
redness) in the injection
site, chills, discomfort
› Dizziness, Headache,
Syncope
› Increased blood pressure,
increased heart rate
SIDE-EFFECTS FOR PERSONS
WITH A HISTORY OF
› Severe allergic reaction or
anaphylaxis 
› Hypersensitivity (such as
lymphadenopathy localized
in the injection site, rashes,
purpura, or hives) or allergic
reaction of any severity to
previous inactivated vaccine
dose or its components,
occurring 4 hours after
administration
PRECAUTIONS TO BE CONSIDERED BEFORE
ADMINISTERING THE VACCINE
› For those with a history of immediate allergic reaction or hypersensitivity to
any other injectable therapy, such as intramuscular, intravenous, or
subcutaneous vaccines unrelated to a component of inactivated COVID-19
vaccines, treatment for severe allergic reactions must be made available.
› For those with concurrent fever, acute illness or those currently experiencing
acute chronic disease attacks, for immunocompromised persons or those
receiving immunosuppressive therapy, or for persons with neurological
conditions, vaccination may be subject to physician advice and supervision.
› For pregnant and breastfeeding women excluded from other priority groups,
vaccination may be subject to physician advice and supervision.
› For persons 59 years old and older, vaccination may be subject to physician
advice and supervision.
THANK YOU FOR LISTENING!

CORPUZ, JAIRUS DERRICK C.

LICUANAN, RAPHAEL JOSE